Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis

被引：1
|
作者：
Colombel, Jean-Frederic [1 ]
Sandborn, William [2 ]
Wolf, Doug [3 ]
Panaccione, Remo [4 ]
Lazar, Andreas [5 ]
Kron, Martina [5 ]
Robinson, Anne [6 ]
Thakkar, Roopal [6 ]
机构：
[1] CHRU, Hop Huriez, Lille, Nord, France
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Atlanta Gastroenterol Associates, Atlanta, GA USA
[4] Univ Calgary, Calgary, AB, Canada
[5] Abbott GmbH & Co KG, Ludwigshafen, Germany
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷
关键词：
D O I：
10.1097/00054725-201212001-00052
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [31] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [32] Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis
    McDermott, Edel
    Murphy, Seamus
    Keegan, Denise
    O'Donoghue, Diarmuid
    Mulcahy, Hugh
    Doherty, Glen
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (02): : 150 - 153
  • [33] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
    Gibson, Peter R.
    Reinisch, Walter
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen W.
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
  • [34] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
  • [35] 52-WEEK CLINICAL EFFICACY WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO FAILED CORTICOSTEROIDS AND/OR IMMUNOSUPPRESSANTS
    Reinisch, W.
    Sandborn, W. J.
    Kumar, A.
    Pollack, P. F.
    Lazar, A.
    Thakkar, R. B.
    GUT, 2011, 60 : A139 - U2002
  • [36] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
    Taxonera, Carlos
    Iborra, Marisa
    Maia Bosca-Watts, Marta
    Rubio, Saioa
    Nantes, Oscar
    Higuera, Rebeca
    Bertoletti, Federico
    Martinez-Montiel, Pilar
    Sierra-Ausin, Monica
    Mancenido, Noemi
    Lazar Perez-Calle, Jose
    Algaba, Alicia
    Olivares, David
    Alba, Cristina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
  • [37] Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
    Rubin, David T.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Afsari, Sonia
    Petersen, Ann Katrin
    Sheffield, James
    Li, Hongjuan
    Silva, Diego
    Lublin, Fred D.
    Cree, Bruce
    Cohen, Jeffrey
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S396 - S396
  • [38] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William J.
    Feagan, Brian G.
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul
    Tarabar, Dino
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
  • [39] A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis
    Law, Cindy C. Y.
    Kayal, Maia
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (02) : 109 - 117
  • [40] Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Bhat, Shubha
    Choi, David
    ANNALS OF PHARMACOTHERAPY, 2025,
12345